Point Therapeutics
75 Kneeland Street
Boston
Massachusetts
02111
United States
Tel: 617-636-0680
Fax: 617-636-0675
57 articles about Point Therapeutics
-
DARA BioSciences, Inc. and Point Therapeutics Announce Consummation of Merger
2/13/2008
-
Update on Point Therapeutics Merger with DARA BioSciences, Inc.
2/11/2008
-
Point Therapeutics May File for Chapter 11
2/4/2008
-
Point Therapeutics Adjourns Meeting of Stockholders to February 12, 2008; DARA BioSciences, Inc. Stockholders Approve Merger with Point Therapeutics
1/30/2008
-
Point Therapeutics Receives Additional Notice of Non-Compliance from NASDAQ
1/10/2008
-
Point Therapeutics Announces Form S-4 Registration Statement Declared Effective by SEC; Special Meeting of Stockholders Set for January 29, 2007
12/27/2007
-
NASDAQ Panel Grants Request of Point Therapeutics for Continued Listing on NASDAQ Capital Market
12/17/2007
-
Point Therapeutics Receives Additional Notice of Non-Compliance from NASDAQ
11/19/2007
-
Point Therapeutics Reports Third Quarter 2007 Financial Results
11/9/2007
-
DARA BioSciences, Inc. to Acquire Point Therapeutics
10/10/2007
-
Point Therapeutics Announces Receipt of Determination Letter From Nasdaq
9/18/2007
-
Point Therapeutics Reports Second Quarter 2007 Financial Results
8/10/2007
-
Point Therapeutics Announces Further Management Reductions: Fires CEO and CFO
7/27/2007
-
Point Therapeutics's Talabostat Clinical Program Put on Clinical Hold by FDA
5/21/2007
-
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
5/15/2007
-
Point Therapeutics Reports First Quarter 2007 Financial Results
5/10/2007
-
Point Therapeutics Announces Preclinical Data Presentations at Upcoming American Association for Cancer Research Annual Meeting
4/13/2007
-
Point Therapeutics Announces Management Change and Additional Information In Compliance With NASDAQ Rules; Dr. Margaret Uprichard, Senior Vice President and Chief Development Officer Resigned
3/26/2007
-
Point Therapeutics Reports Fourth Quarter and Year-End 2006 Financial Results
3/16/2007
-
Point Therapeutics Receives Letter from Nasdaq Citing Non-Compliance with Minimum Bid Price Rules
3/13/2007